AR and neoplasm: Although the above methods are initially effective in blocking the AR signaling, patients eventually develop castration-resistant prostate PCa (CRPC), which is characterized by rising serum prostate specific antigen (PSA) and renewed tumour growth [2,3,46,47], with subsequent poor patient survival [48,49].